Innate Pharma highlights increased lacutamab activity in TELLOMAK study

Innate Pharma announced that interim efficacy results from the TELLOMAK Phase 2 study in advanced Mycosis Fungoides, or MF, according to updated lymph node classification confirms clinical activity and favorable safety profile of lacutamab, an anti-KIR3DL2 antibody. The data were presented at the 17th International Conference on Malignant Lymphoma, in Lugano, Switzerland. As of March 4, 2022, data cutoff, patients in the KIR3DL2-expressing MF cochort received a median of 4 prior systemic therapies, and had a median follow-up of 12.2 months. In the KIR3DL2 non-expressing cohort, patients received a median of 4.5 prior systemic therapies and had a median follow-up of 13.8 months. Results showed that lacutamab produced an increased global objective response rate of 42.9% in patients with KIR3DL2 greater than or equal to 1% MF, including 2 complete responses and 7 partial responses. Clinical Benefit Rate remained unchanged at 85.7%. In Cohort 3, comprising 18 patients with KIR3DL2 less than 1% MF, findings remain unchanged.